Promis Neurosciences (PMN) Stock Price, News & Analysis

Company Overview

ProMIS Neurosciences Inc. (NASDAQ: PMN) is a clinical-stage biotechnology company focused on developing antibody-based treatments for neurodegenerative diseases. The company uses its proprietary technology platform to identify disease-related misfolded proteins and selectively target toxic forms that may contribute to neuronal damage.

ProMIS’s lead investigational product is PMN310, an antibody designed to target toxic soluble amyloid-beta oligomers associated with Alzheimer’s disease while avoiding healthier forms of amyloid-beta. The company is also researching potential therapies for other neurodegenerative conditions, including amyotrophic lateral sclerosis, Parkinson’s disease and related disorders involving misfolded proteins.

ProMIS Neurosciences has roots in research conducted by academic and biotechnology collaborators in Canada and the United States and maintains a development focus on advancing treatments through clinical testing. Its programs are investigational and have not been established as safe or effective for commercial use.

Key Stats

• Today's Range: $9.06 to $10.15
• 50-Day Range: $9.12 to $15.36
• 52-Week Range: $6.27 to $27.40
• Volume: 18,840 shs
• Average Volume: 35,846 shs
• Market Capitalization: $86.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $34.00
• Consensus Rating: Moderate Buy

Promis Neurosciences Stock Analysis - MarketRank™

Promis Neurosciences scored higher than 64% of companies evaluated by MarketBeat, and ranked 309th out of 882 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Promis Neurosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 2 strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Promis Neurosciences has a consensus price target of $34.00, representing about 253.8% upside from its current price of $9.61.

Amount of Analyst Coverage

Promis Neurosciences has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Promis Neurosciences are expected to grow in the coming year, from ($5.29) to ($4.05) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Promis Neurosciences is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Promis Neurosciences is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.70% of the float of Promis Neurosciences has been sold short.

Short Interest Ratio / Days to Cover

Promis Neurosciences has a short interest ratio ("days to cover") of 7.12.

Change versus previous month

Short interest in Promis Neurosciences has recently decreased by 0.59%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Promis Neurosciences does not currently pay a dividend.

Dividend Growth

Promis Neurosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.46

News Sentiment

Promis Neurosciences has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Promis Neurosciences this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for PMN on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added Promis Neurosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Promis Neurosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.50% of the stock of Promis Neurosciences is held by insiders.

Percentage Held by Institutions

50.13% of the stock of Promis Neurosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/12/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PMN
• CIK: 1374339
• Web: www.promisneurosciences.com
• Phone: (416) 847-6898
• Fax: N/A
• Employees: 11
• Year Founded: 2001

Price Target and Rating

• Average Price Target for Promis Neurosciences: $34.00
• High Price Target: $69.00
• Low Price Target: $18.00
• Potential Upside/Downside: +253.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($8.54)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$39.72 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -143.09%
• Return on Assets: -109.15%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.85
• Quick Ratio: 7.85

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.58) per share
• Price / Book: -16.57

Miscellaneous

• Outstanding Shares: 8,970,000
• Free Float: 8,833,000
• Market Cap: $86.20 million
• Optionable: Not Optionable
• Beta: -0.26